16th Jul 2015 09:17
LONDON (Alliance News) - Contract research organisation Cyprotex PLC on Thursday said it has launched a new bioservices division.
The new division will complement its existing ADME-Tox business and will provide access to cell-based efficacy screening services.
Shares in Cyprotex were down 0.9% to 53.00 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L